Accessibility Menu
MabCure logo

MabCure(OTC) MBCI

Market Cap$12.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-100%
5 Year-82%
1 Year+100%
1 Month+0%
$0.00
+50.00%
+0.00Today
MabCure last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-29
MabCure stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-33.33%USD 0.002026-07-21
1 month+0%USD 0.002026-06-23
3 month-50%USD 0.002026-04-28
Year to date+100%USD 0.002025-12-30
1 year+100%USD 0.002025-07-17
3 year-33.33%USD 0.002023-07-27
5 year-81.82%USD 0.002021-07-30
Since inception-99.98%USD 1.012007-12-05

MabCure Financials at a Glance

Market Cap

$12.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$500.00K

Net Income (TTM)

-$12.45M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-9.22 (Low)

Price

$0.00

Volume

2,167

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jul 16, 2024

MBCI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MabCure

MabCure Inc. is a development stage company focused on the advancement of proprietary antibody technology for early cancer detection and the creation of targeted therapeutics. Founded in 2006 and based in White Plains, New York, the company aims to revolutionize cancer diagnostics and treatment through innovative solutions.

Products and Services
  • Proprietary antibody technology for cancer detection
  • Development of monoclonal antibodies targeting specific cancer markers
  • Creation of therapeutics aimed at treating various cancers
Growth Outlook
  • Significant market potential in cancer diagnostics and therapeutics
  • Increasing demand for early detection technologies in healthcare
  • Strategic partnerships could enhance research and development capabilities
Financial Highlights
  • Recent quarterly revenue of 500,000, indicating potential market traction
  • Trailing twelve months (TTM) gross profit margin stands at 100%
  • Current ratio of 0.17 suggests liquidity challenges but manageable debt levels
MabCure Inc. operates in the medical and pharmaceutical industry, focusing on innovative solutions for cancer care. The company's proprietary technology positions it well within a growing market, driven by increasing awareness and demand for early cancer detection methods. Recent financial data indicates a revenue of 500,000 in the latest quarter, showcasing the potential for market traction. The TTM gross profit margin of 100% reflects the company's ability to generate profit from its core operations, although liquidity challenges are evident with a current ratio of 0.17. Overall, MabCure Inc. presents an intriguing opportunity for investors interested in the healthcare sector, particularly in the realm of cancer diagnostics and therapeutics.
AI Generated • Jul 18, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

White Plains, NY 10605, US

MBCI Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-141.95%

Net Income Margin

-2490.30%

Return on Equity

-127.05%

Return on Capital

-17.16%

Return on Assets

-258.80%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

64.36M

Volume

2.17K

Avg. Volume

874.191

Financials (TTM)

Gross Profit

$500.00K

Operating Income

-$708.92K

EBITDA

-$12.05M

Operating Cash Flow

-$61.39K

Capital Expenditure

$0.00

Free Cash Flow

-$61.39K

Cash & ST Invst.

$146.44K

Total Debt

$261.16K

MabCure Performance Analysis

MabCure sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12011-03-31N/A
Q22011-06-30N/A
Q32011-09-30N/A
Q42011-12-31N/A
MabCure sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12011-03-3128.4%
Q22011-06-30-11.0%
Q32011-09-3044.4%
Q42011-12-31-3900.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q4 2011YOY CHG

Revenue

$500.00K

N/A

Gross Profit

$500.00K

N/A

Gross Margin

100.00%

N/A

Market Cap

$12.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.30K

N/A

Employees

3

N/A

Net Income

-$11.19M

-1658.7%

EBITDA

-$11.17M

-4782.1%

Quarterly Fundamentals

Name
Q4 2011YOY CHG

Total Cash

$146.44K

+4188.0%

Total Debt

$261.16K

+40.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$261.16K

+54.0%

Return on Assets

-2.59%

N/A

Return on Invested Capital

-18.31%

N/A

Free Cash Flow

$145.25K

+247.2%

Operating Cash Flow

$145.25K

+261.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QOILQuest Oil Corporation
$0.00+0.00%
SKPISky Petroleum, Inc.
$0.00+0.00%
BPIGFBPI Energy Holdings, Inc
$0.00+0.00%
GSLOGo Solar USA, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About MBCI

What is the current price of MabCure?

MabCure is trading at $0.00 per share.

What is the 52-week range for MabCure?

Over the past 52 weeks, MabCure has traded between $0.00 and $0.00.

How much debt does MabCure have?

MabCure total debt is unavailable.

How much cash does MabCure have on hand?

MabCure does not have cash on hand data available.

What is MabCure’s dividend yield?

MabCure does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services